Therapeutic effects and mechanisms of Tripterygium wilfordii extracts in rheumatoid arthritis: a systematic review and meta-analysis of preclinical studies
Tripterygium polyglycosides (TG), Triptolide (TP), and Celastrol (CEL), which are extracts from Tripterygium wilfordii Hook F (TwHF), are renowned for their anti-inflammatory and immunomodulatory properties in the treatment of rheumatoid arthritis (RA). However, a comprehensive systematic review and...
Saved in:
| Published in | Scientific reports Vol. 15; no. 1; pp. 27960 - 26 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
31.07.2025
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Tripterygium polyglycosides (TG), Triptolide (TP), and Celastrol (CEL), which are extracts from
Tripterygium wilfordii
Hook F (TwHF), are renowned for their anti-inflammatory and immunomodulatory properties in the treatment of rheumatoid arthritis (RA). However, a comprehensive systematic review and meta-analysis of preclinical evidence supporting the use of
Tripterygium wilfordii
extracts for RA has not yet been conducted. This study aimed to conduct a systematic review and meta-analysis to evaluate the therapeutic effects and potential underlying mechanisms of
Tripterygium wilfordii
extracts in CIA model of RA. Six electronic databases, including PubMed, Embase, Web of Science, Cochrane Library, Scopus, and Ovid, were searched from their inception to June 2024. The methodological quality was assessed via SYRCLE’s risk of bias tool. Statistical analyses were performed using Stata 18.0 software and Review Manager 5.4.1 software. This study included 32 articles involving 568 animals. The results revealed that
Tripterygium wilfordii
extracts significantly reduced joint manifestations (arthritis index, paw swelling degree, and paw thickness); histopathological changes in joints (histopathological score, cartilage damage, bone destruction, synovial hyperplasia, pannus formation, and inflammatory cell infiltration); levels of related cytokines (TNF-α, IL-1β, IL-6, IL-23, IFN-γ, and IL-17); anti-type II collagen antibodies; and T-cell subsets (CD4
+
T cells, Th1 cells, and Th17 cells). Moreover,
Tripterygium wilfordii
extracts significantly increased the levels of relevant cytokines (IL-10, IL-4, and TGF-β) and the number of Treg cells compared with those in the control group. However, animal species and sex, extract category and dosage, and treatment duration were identified as important factors influencing the above results.
Tripterygium wilfordii
extracts (TG, TP and CEL) exhibit promising therapeutic effects and mechanisms in the treatment of RA. But the effect characteristics and mechanisms vary among different
Tripterygium wilfordii
extracts. These specific effects and mechanisms also vary depending on the treatment duration and dosage. |
|---|---|
| AbstractList | Tripterygium polyglycosides (TG), Triptolide (TP), and Celastrol (CEL), which are extracts from Tripterygium wilfordii Hook F (TwHF), are renowned for their anti-inflammatory and immunomodulatory properties in the treatment of rheumatoid arthritis (RA). However, a comprehensive systematic review and meta-analysis of preclinical evidence supporting the use of Tripterygium wilfordii extracts for RA has not yet been conducted. This study aimed to conduct a systematic review and meta-analysis to evaluate the therapeutic effects and potential underlying mechanisms of Tripterygium wilfordii extracts in CIA model of RA. Six electronic databases, including PubMed, Embase, Web of Science, Cochrane Library, Scopus, and Ovid, were searched from their inception to June 2024. The methodological quality was assessed via SYRCLE’s risk of bias tool. Statistical analyses were performed using Stata 18.0 software and Review Manager 5.4.1 software. This study included 32 articles involving 568 animals. The results revealed that Tripterygium wilfordii extracts significantly reduced joint manifestations (arthritis index, paw swelling degree, and paw thickness); histopathological changes in joints (histopathological score, cartilage damage, bone destruction, synovial hyperplasia, pannus formation, and inflammatory cell infiltration); levels of related cytokines (TNF-α, IL-1β, IL-6, IL-23, IFN-γ, and IL-17); anti-type II collagen antibodies; and T-cell subsets (CD4+ T cells, Th1 cells, and Th17 cells). Moreover, Tripterygium wilfordii extracts significantly increased the levels of relevant cytokines (IL-10, IL-4, and TGF-β) and the number of Treg cells compared with those in the control group. However, animal species and sex, extract category and dosage, and treatment duration were identified as important factors influencing the above results. Tripterygium wilfordii extracts (TG, TP and CEL) exhibit promising therapeutic effects and mechanisms in the treatment of RA. But the effect characteristics and mechanisms vary among different Tripterygium wilfordii extracts. These specific effects and mechanisms also vary depending on the treatment duration and dosage. Tripterygium polyglycosides (TG), Triptolide (TP), and Celastrol (CEL), which are extracts from Tripterygium wilfordii Hook F (TwHF), are renowned for their anti-inflammatory and immunomodulatory properties in the treatment of rheumatoid arthritis (RA). However, a comprehensive systematic review and meta-analysis of preclinical evidence supporting the use of Tripterygium wilfordii extracts for RA has not yet been conducted. This study aimed to conduct a systematic review and meta-analysis to evaluate the therapeutic effects and potential underlying mechanisms of Tripterygium wilfordii extracts in CIA model of RA. Six electronic databases, including PubMed, Embase, Web of Science, Cochrane Library, Scopus, and Ovid, were searched from their inception to June 2024. The methodological quality was assessed via SYRCLE’s risk of bias tool. Statistical analyses were performed using Stata 18.0 software and Review Manager 5.4.1 software. This study included 32 articles involving 568 animals. The results revealed that Tripterygium wilfordii extracts significantly reduced joint manifestations (arthritis index, paw swelling degree, and paw thickness); histopathological changes in joints (histopathological score, cartilage damage, bone destruction, synovial hyperplasia, pannus formation, and inflammatory cell infiltration); levels of related cytokines (TNF-α, IL-1β, IL-6, IL-23, IFN-γ, and IL-17); anti-type II collagen antibodies; and T-cell subsets (CD4 + T cells, Th1 cells, and Th17 cells). Moreover, Tripterygium wilfordii extracts significantly increased the levels of relevant cytokines (IL-10, IL-4, and TGF-β) and the number of Treg cells compared with those in the control group. However, animal species and sex, extract category and dosage, and treatment duration were identified as important factors influencing the above results. Tripterygium wilfordii extracts (TG, TP and CEL) exhibit promising therapeutic effects and mechanisms in the treatment of RA. But the effect characteristics and mechanisms vary among different Tripterygium wilfordii extracts. These specific effects and mechanisms also vary depending on the treatment duration and dosage. Tripterygium polyglycosides (TG), Triptolide (TP), and Celastrol (CEL), which are extracts from Tripterygium wilfordii Hook F (TwHF), are renowned for their anti-inflammatory and immunomodulatory properties in the treatment of rheumatoid arthritis (RA). However, a comprehensive systematic review and meta-analysis of preclinical evidence supporting the use of Tripterygium wilfordii extracts for RA has not yet been conducted. This study aimed to conduct a systematic review and meta-analysis to evaluate the therapeutic effects and potential underlying mechanisms of Tripterygium wilfordii extracts in CIA model of RA. Six electronic databases, including PubMed, Embase, Web of Science, Cochrane Library, Scopus, and Ovid, were searched from their inception to June 2024. The methodological quality was assessed via SYRCLE's risk of bias tool. Statistical analyses were performed using Stata 18.0 software and Review Manager 5.4.1 software. This study included 32 articles involving 568 animals. The results revealed that Tripterygium wilfordii extracts significantly reduced joint manifestations (arthritis index, paw swelling degree, and paw thickness); histopathological changes in joints (histopathological score, cartilage damage, bone destruction, synovial hyperplasia, pannus formation, and inflammatory cell infiltration); levels of related cytokines (TNF-α, IL-1β, IL-6, IL-23, IFN-γ, and IL-17); anti-type II collagen antibodies; and T-cell subsets (CD4 T cells, Th1 cells, and Th17 cells). Moreover, Tripterygium wilfordii extracts significantly increased the levels of relevant cytokines (IL-10, IL-4, and TGF-β) and the number of Treg cells compared with those in the control group. However, animal species and sex, extract category and dosage, and treatment duration were identified as important factors influencing the above results. Tripterygium wilfordii extracts (TG, TP and CEL) exhibit promising therapeutic effects and mechanisms in the treatment of RA. But the effect characteristics and mechanisms vary among different Tripterygium wilfordii extracts. These specific effects and mechanisms also vary depending on the treatment duration and dosage. Abstract Tripterygium polyglycosides (TG), Triptolide (TP), and Celastrol (CEL), which are extracts from Tripterygium wilfordii Hook F (TwHF), are renowned for their anti-inflammatory and immunomodulatory properties in the treatment of rheumatoid arthritis (RA). However, a comprehensive systematic review and meta-analysis of preclinical evidence supporting the use of Tripterygium wilfordii extracts for RA has not yet been conducted. This study aimed to conduct a systematic review and meta-analysis to evaluate the therapeutic effects and potential underlying mechanisms of Tripterygium wilfordii extracts in CIA model of RA. Six electronic databases, including PubMed, Embase, Web of Science, Cochrane Library, Scopus, and Ovid, were searched from their inception to June 2024. The methodological quality was assessed via SYRCLE’s risk of bias tool. Statistical analyses were performed using Stata 18.0 software and Review Manager 5.4.1 software. This study included 32 articles involving 568 animals. The results revealed that Tripterygium wilfordii extracts significantly reduced joint manifestations (arthritis index, paw swelling degree, and paw thickness); histopathological changes in joints (histopathological score, cartilage damage, bone destruction, synovial hyperplasia, pannus formation, and inflammatory cell infiltration); levels of related cytokines (TNF-α, IL-1β, IL-6, IL-23, IFN-γ, and IL-17); anti-type II collagen antibodies; and T-cell subsets (CD4+ T cells, Th1 cells, and Th17 cells). Moreover, Tripterygium wilfordii extracts significantly increased the levels of relevant cytokines (IL-10, IL-4, and TGF-β) and the number of Treg cells compared with those in the control group. However, animal species and sex, extract category and dosage, and treatment duration were identified as important factors influencing the above results. Tripterygium wilfordii extracts (TG, TP and CEL) exhibit promising therapeutic effects and mechanisms in the treatment of RA. But the effect characteristics and mechanisms vary among different Tripterygium wilfordii extracts. These specific effects and mechanisms also vary depending on the treatment duration and dosage. Tripterygium polyglycosides (TG), Triptolide (TP), and Celastrol (CEL), which are extracts from Tripterygium wilfordii Hook F (TwHF), are renowned for their anti-inflammatory and immunomodulatory properties in the treatment of rheumatoid arthritis (RA). However, a comprehensive systematic review and meta-analysis of preclinical evidence supporting the use of Tripterygium wilfordii extracts for RA has not yet been conducted. This study aimed to conduct a systematic review and meta-analysis to evaluate the therapeutic effects and potential underlying mechanisms of Tripterygium wilfordii extracts in CIA model of RA. Six electronic databases, including PubMed, Embase, Web of Science, Cochrane Library, Scopus, and Ovid, were searched from their inception to June 2024. The methodological quality was assessed via SYRCLE's risk of bias tool. Statistical analyses were performed using Stata 18.0 software and Review Manager 5.4.1 software. This study included 32 articles involving 568 animals. The results revealed that Tripterygium wilfordii extracts significantly reduced joint manifestations (arthritis index, paw swelling degree, and paw thickness); histopathological changes in joints (histopathological score, cartilage damage, bone destruction, synovial hyperplasia, pannus formation, and inflammatory cell infiltration); levels of related cytokines (TNF-α, IL-1β, IL-6, IL-23, IFN-γ, and IL-17); anti-type II collagen antibodies; and T-cell subsets (CD4+ T cells, Th1 cells, and Th17 cells). Moreover, Tripterygium wilfordii extracts significantly increased the levels of relevant cytokines (IL-10, IL-4, and TGF-β) and the number of Treg cells compared with those in the control group. However, animal species and sex, extract category and dosage, and treatment duration were identified as important factors influencing the above results. Tripterygium wilfordii extracts (TG, TP and CEL) exhibit promising therapeutic effects and mechanisms in the treatment of RA. But the effect characteristics and mechanisms vary among different Tripterygium wilfordii extracts. These specific effects and mechanisms also vary depending on the treatment duration and dosage.Tripterygium polyglycosides (TG), Triptolide (TP), and Celastrol (CEL), which are extracts from Tripterygium wilfordii Hook F (TwHF), are renowned for their anti-inflammatory and immunomodulatory properties in the treatment of rheumatoid arthritis (RA). However, a comprehensive systematic review and meta-analysis of preclinical evidence supporting the use of Tripterygium wilfordii extracts for RA has not yet been conducted. This study aimed to conduct a systematic review and meta-analysis to evaluate the therapeutic effects and potential underlying mechanisms of Tripterygium wilfordii extracts in CIA model of RA. Six electronic databases, including PubMed, Embase, Web of Science, Cochrane Library, Scopus, and Ovid, were searched from their inception to June 2024. The methodological quality was assessed via SYRCLE's risk of bias tool. Statistical analyses were performed using Stata 18.0 software and Review Manager 5.4.1 software. This study included 32 articles involving 568 animals. The results revealed that Tripterygium wilfordii extracts significantly reduced joint manifestations (arthritis index, paw swelling degree, and paw thickness); histopathological changes in joints (histopathological score, cartilage damage, bone destruction, synovial hyperplasia, pannus formation, and inflammatory cell infiltration); levels of related cytokines (TNF-α, IL-1β, IL-6, IL-23, IFN-γ, and IL-17); anti-type II collagen antibodies; and T-cell subsets (CD4+ T cells, Th1 cells, and Th17 cells). Moreover, Tripterygium wilfordii extracts significantly increased the levels of relevant cytokines (IL-10, IL-4, and TGF-β) and the number of Treg cells compared with those in the control group. However, animal species and sex, extract category and dosage, and treatment duration were identified as important factors influencing the above results. Tripterygium wilfordii extracts (TG, TP and CEL) exhibit promising therapeutic effects and mechanisms in the treatment of RA. But the effect characteristics and mechanisms vary among different Tripterygium wilfordii extracts. These specific effects and mechanisms also vary depending on the treatment duration and dosage. |
| ArticleNumber | 27960 |
| Author | Feng, Zhe Chen, Xiaoying Lu, Yan Huang, Shuai Chen, Kai Zhou, Lingling Zhou, Xueping |
| Author_xml | – sequence: 1 givenname: Kai surname: Chen fullname: Chen, Kai organization: The First Clinical Medical College, Nanjing University of Chinese Medicine – sequence: 2 givenname: Xiaoying surname: Chen fullname: Chen, Xiaoying organization: The First Clinical Medical College, Nanjing University of Chinese Medicine – sequence: 3 givenname: Shuai surname: Huang fullname: Huang, Shuai organization: The First Clinical Medical College, Nanjing University of Chinese Medicine – sequence: 4 givenname: Lingling surname: Zhou fullname: Zhou, Lingling organization: College of Pharmacy, Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine – sequence: 5 givenname: Xueping surname: Zhou fullname: Zhou, Xueping organization: The First Clinical Medical College, Nanjing University of Chinese Medicine – sequence: 6 givenname: Yan surname: Lu fullname: Lu, Yan email: luyanpr@qq.com organization: Department of Rheumatology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine – sequence: 7 givenname: Zhe surname: Feng fullname: Feng, Zhe email: 260583@njucm.edu.cn organization: The First Clinical Medical College, Nanjing University of Chinese Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40745443$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks9u1DAQxiNUREvpC3BAlrhwCfjPuEm4oYqWSpW4LGfLa493vUriYDu0-yy8LO5mKYgDc7E1_s03Y_t7WZ2MYcSqes3oe0ZF-yEBk11bUy5rJjiwunlWnXEKsuaC85O_9qfVRUo7WkLyDlj3ojoF2oAEEGfVz9UWo55wzt4QdA5NTkSPlgxotnr0aUgkOLKKfsoY9xs_D-Te9y5E6z3Bhxz1Y4UfSdziPOgcvCU65m302aePRJO0TxnLQdGP-MPj_VE-61qPut8nf-gwRTS9H73RPUl5th7Tq-q5033Ci-N6Xn27_ry6-lLffb25vfp0VxshRVNbMFII17kO9NpBI5uOQbuWnYbWCC2t04x11JWElZY3hknBLq1spUBsOYrz6nbRtUHv1BT9oONeBe3VIRHiRpUbedOjQopcNOAcRQYdmFZYA7aj0AA4u2ZF692iNcXwfcaU1eCTwb7XI4Y5KcHLzG0JWdC3_6C7MMfyJAvFmYBLKNSbIzWvB7RP4_3-wgLwBTAxpBTRPSGMqkerqMUqqlhFHayimlIklqJU4HGD8U_v_1T9ArOawn0 |
| Cites_doi | 10.1007/s11010-022-04492-3 10.1136/annrheumdis-2013-204807 10.1002/iid3.1322 10.1016/j.clim.2023.109749 10.1080/14786410802187783 10.1016/j.jaut.2023.103148 10.1016/j.jaut.2019.102400 10.1016/j.phrs.2019.104459 10.1016/j.jep.2023.116416 10.1016/j.jcma.2015.10.012 10.12701/jyms.2022.00773 10.1016/j.intimp.2016.06.029 10.1016/j.jep.2021.114714 10.3389/fphar.2022.938849 10.1186/1749-8546-4-13 10.1016/j.intimp.2022.109241 10.1002/ar.22479 10.1016/j.jep.2023.116211 10.1016/j.eng.2024.04.003 10.1093/ilar/ilu043 10.1016/j.phrs.2022.106405 10.1002/ptr.7681 10.1016/j.jep.2024.117770 10.1016/j.ard.2025.04.009 10.3390/ijms19020376 10.1136/bmj.n71 10.1016/S0140-6736(23)01525-8 10.1016/j.phymed.2023.154875 10.1186/s13075-018-1563-6 10.3389/fcimb.2019.00204 10.1016/j.jep.2019.112428 10.1016/j.jep.2023.116782 10.1016/j.arr.2024.102643 10.1016/j.autrev.2023.103359 10.1016/j.molimm.2021.11.002 10.1080/08923973.2022.2086139 10.1016/j.apsb.2023.05.025 10.1055/s-2007-967136 10.1097/JCMA.0000000000000029 10.1055/s-2006-947240 10.1038/s41598-023-48248-5 10.1007/s10753-024-02060-z 10.1177/01410768221093551 10.1016/j.bcp.2006.08.027 10.1016/j.biopha.2023.115417 10.1186/1471-2288-14-43 10.1016/j.lfs.2017.01.004 10.3389/fphar.2022.908227 10.1038/s41413-018-0016-9 10.1002/eji.202249962 10.3389/fphar.2023.1113810 10.1111/bcpt.13880 10.1080/13510002.2021.2004047 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025 2025. The Author(s). The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI Q9U 7X8 DOA |
| DOI | 10.1038/s41598-025-13241-7 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Database (Proquest) ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Proquest Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 26 |
| ExternalDocumentID | oai_doaj_org_article_e0e2374ff0e1494c83dc4d904744fdb1 40745443 10_1038_s41598_025_13241_7 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GrantInformation_xml | – fundername: Natural Science Foundation of Jiangsu Province grantid: BK20211299 funderid: https://doi.org/10.13039/501100004608 – fundername: Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions grantid: 24KJA360003 funderid: https://doi.org/10.13039/501100013280 – fundername: National Natural Science Foundation of China grantid: 82374187 funderid: https://doi.org/10.13039/501100001809 – fundername: Natural Science Foundation of Jiangsu Province grantid: BK20211299 – fundername: Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions grantid: 24KJA360003 – fundername: National Natural Science Foundation of China grantid: 82374187 |
| GroupedDBID | 0R~ 4.4 53G 5VS 7X7 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD AASML ABDBF ABUWG ACGFS ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M1P M2P M7P M~E NAO OK1 PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AARCD AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM 3V. 7XB 88A 8FK K9. M48 PKEHL PQEST PQUKI Q9U 7X8 PUEGO |
| ID | FETCH-LOGICAL-c3537-d4c533f9f94abf47579148b59a48c3a5dfa1190f59ad5d27c15316d5853ee82e3 |
| IEDL.DBID | AAJSJ |
| ISSN | 2045-2322 |
| IngestDate | Wed Aug 27 01:32:06 EDT 2025 Fri Aug 01 18:25:06 EDT 2025 Wed Aug 13 03:14:06 EDT 2025 Thu Aug 07 06:28:14 EDT 2025 Thu Aug 07 07:32:40 EDT 2025 Sun Aug 17 01:18:08 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Animal model Preclinical studies extracts Rheumatoid arthritis Meta-analysis Tripterygium wilfordii extracts |
| Language | English |
| License | 2025. The Author(s). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3537-d4c533f9f94abf47579148b59a48c3a5dfa1190f59ad5d27c15316d5853ee82e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.nature.com/articles/s41598-025-13241-7 |
| PMID | 40745443 |
| PQID | 3235213464 |
| PQPubID | 2041939 |
| PageCount | 26 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e0e2374ff0e1494c83dc4d904744fdb1 proquest_miscellaneous_3235388885 proquest_journals_3235213464 pubmed_primary_40745443 crossref_primary_10_1038_s41598_025_13241_7 springer_journals_10_1038_s41598_025_13241_7 |
| PublicationCentury | 2000 |
| PublicationDate | 20250731 |
| PublicationDateYYYYMMDD | 2025-07-31 |
| PublicationDate_xml | – month: 7 year: 2025 text: 20250731 day: 31 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2025 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | M Ritskes-Hoitinga (13241_CR18) 2022; 115 13241_CR46 WS Chen (13241_CR59) 2020; 40 YC He (13241_CR55) 2021; 19 QW Lv (13241_CR17) 2015; 74 S Wang (13241_CR21) 2023; 53 CR Hooijmans (13241_CR23) 2014; 14 J Yang (13241_CR45) 2022; 112 L Zeng (13241_CR10) 2024; 14 Y Guo (13241_CR28) 2016; 39 Z Feng (13241_CR13) 2022; 184 C Xiao (13241_CR41) 2009; 23 Y Huang (13241_CR30) 2023; 133 X Zhang (13241_CR9) 2023; 255 13241_CR50 X Liu (13241_CR34) 2024; 12 C Xiao (13241_CR39) 2006; 72 X Wang (13241_CR16) 2017; 171 J Peng (13241_CR36) 2019; 9 H Jiang (13241_CR31) 2022; 283 N Lin (13241_CR33) 2007; 73 J Chen (13241_CR25) 2019; 39 LQ Shi (13241_CR60) 2015; 36 Y Zhang (13241_CR53) 2023; 166 J Li (13241_CR32) 2023; 14 F Cao (13241_CR2) 2023; 22 L Zhang (13241_CR52) 2023; 317 Y Xu (13241_CR5) 2023; 13 13241_CR8 P Yang (13241_CR44) 2020; 250 GM Yu (13241_CR47) 2021; 26 YJ Yang (13241_CR51) 2023; 116 A Di Matteo (13241_CR4) 2023; 402 M Yan (13241_CR43) 2022; 13 X Zhang (13241_CR11) 2024; 142 Y Guo (13241_CR27) 2016; 79 L Mu (13241_CR35) 2023; 310 S Cong (13241_CR26) 2023; 37 X Song (13241_CR37) 2024; 324 C Xiao (13241_CR40) 2009; 4 A Finckh (13241_CR3) 2022; 18 JS Kong (13241_CR20) 2023; 40 X Wang (13241_CR56) 2025; 104 YZ Zhou (13241_CR15) 2018; 20 Y Luo (13241_CR12) 2023; 307 LX Guo (13241_CR29) 2019; 149 Chinese Rheumatology Association (13241_CR7) 2018; 57 L Ao (13241_CR24) 2022; 141 J Wang (13241_CR38) 2012; 295 Y Zhu (13241_CR49) 2022; 13 MY Shen (13241_CR54) 2022; 44 W Jin (13241_CR58) 2025; 84 W Zhang (13241_CR48) 2007; 73 MJ Page (13241_CR22) 2021; 372 13241_CR19 HU Scherer (13241_CR14) 2020; 110 Q Guo (13241_CR57) 2018; 6 P Prasad (13241_CR6) 2023; 478 E Xing (13241_CR42) 2019; 82 P Brown (13241_CR1) 2024; 384 |
| References_xml | – volume: 478 start-page: 69 issue: 1 year: 2023 ident: 13241_CR6 publication-title: Mol. Cell. Biochem. doi: 10.1007/s11010-022-04492-3 – volume: 74 start-page: 1078 issue: 6 year: 2015 ident: 13241_CR17 publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2013-204807 – volume: 12 start-page: e1322 issue: 6 year: 2024 ident: 13241_CR34 publication-title: Immun. Inflamm. Dis. doi: 10.1002/iid3.1322 – volume: 255 start-page: 109749 year: 2023 ident: 13241_CR9 publication-title: Clin. Immunol. doi: 10.1016/j.clim.2023.109749 – volume: 36 start-page: 3416 issue: 23 year: 2015 ident: 13241_CR60 publication-title: Int. J. Lab. Med. – volume: 18 start-page: 591 issue: 10 year: 2022 ident: 13241_CR3 publication-title: Nat. Rev. Rheumatol. – volume: 23 start-page: 1699 issue: 18 year: 2009 ident: 13241_CR41 publication-title: Nat. Prod. Res. doi: 10.1080/14786410802187783 – volume: 142 start-page: 103148 year: 2024 ident: 13241_CR11 publication-title: J. Autoimmun. doi: 10.1016/j.jaut.2023.103148 – volume: 110 start-page: 102400 year: 2020 ident: 13241_CR14 publication-title: J. Autoimmun. doi: 10.1016/j.jaut.2019.102400 – volume: 149 start-page: 104459 year: 2019 ident: 13241_CR29 publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2019.104459 – volume: 310 start-page: 116416 year: 2023 ident: 13241_CR35 publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2023.116416 – volume: 79 start-page: 264 issue: 5 year: 2016 ident: 13241_CR27 publication-title: J. Chin. Med. Assoc. doi: 10.1016/j.jcma.2015.10.012 – volume: 40 start-page: 23 issue: 1 year: 2023 ident: 13241_CR20 publication-title: J. Yeungnam Med. Sci. doi: 10.12701/jyms.2022.00773 – volume: 39 start-page: 79 year: 2016 ident: 13241_CR28 publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2016.06.029 – volume: 283 start-page: 114714 year: 2022 ident: 13241_CR31 publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2021.114714 – volume: 13 start-page: 938849 year: 2022 ident: 13241_CR49 publication-title: Front. Pharmacol. doi: 10.3389/fphar.2022.938849 – volume: 4 start-page: 13 year: 2009 ident: 13241_CR40 publication-title: Chin. MED-UK doi: 10.1186/1749-8546-4-13 – volume: 112 start-page: 109241 year: 2022 ident: 13241_CR45 publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2022.109241 – volume: 40 start-page: 5250 issue: 24 year: 2020 ident: 13241_CR59 publication-title: Chin. J. Gerontol. – volume: 295 start-page: 922 issue: 6 year: 2012 ident: 13241_CR38 publication-title: Anat. Rec doi: 10.1002/ar.22479 – volume: 307 start-page: 116211 year: 2023 ident: 13241_CR12 publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2023.116211 – ident: 13241_CR50 doi: 10.1016/j.eng.2024.04.003 – ident: 13241_CR19 doi: 10.1093/ilar/ilu043 – volume: 184 start-page: 106405 year: 2022 ident: 13241_CR13 publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2022.106405 – volume: 37 start-page: 1242 issue: 4 year: 2023 ident: 13241_CR26 publication-title: Phytother Res. doi: 10.1002/ptr.7681 – volume: 324 start-page: 117770 year: 2024 ident: 13241_CR37 publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2024.117770 – volume: 84 start-page: 1104 issue: 6 year: 2025 ident: 13241_CR58 publication-title: Ann. Rheum. Dis. doi: 10.1016/j.ard.2025.04.009 – ident: 13241_CR8 doi: 10.3390/ijms19020376 – volume: 372 start-page: n71 year: 2021 ident: 13241_CR22 publication-title: BMJ-Brit Med. J. doi: 10.1136/bmj.n71 – volume: 402 start-page: 2019 issue: 10416 year: 2023 ident: 13241_CR4 publication-title: Lancet doi: 10.1016/S0140-6736(23)01525-8 – volume: 116 start-page: 154875 year: 2023 ident: 13241_CR51 publication-title: Phytomedicine doi: 10.1016/j.phymed.2023.154875 – volume: 20 start-page: 70 issue: 1 year: 2018 ident: 13241_CR15 publication-title: Arthritis Res. Ther. doi: 10.1186/s13075-018-1563-6 – volume: 9 start-page: 204 year: 2019 ident: 13241_CR36 publication-title: Front. Cell. Infect. Mi doi: 10.3389/fcimb.2019.00204 – volume: 250 start-page: 112428 year: 2020 ident: 13241_CR44 publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2019.112428 – volume: 317 start-page: 116782 year: 2023 ident: 13241_CR52 publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2023.116782 – volume: 104 start-page: 102643 year: 2025 ident: 13241_CR56 publication-title: Ageing Res. Rev. doi: 10.1016/j.arr.2024.102643 – volume: 22 start-page: 103359 issue: 8 year: 2023 ident: 13241_CR2 publication-title: Autoimmun. Rev. doi: 10.1016/j.autrev.2023.103359 – volume: 141 start-page: 13 year: 2022 ident: 13241_CR24 publication-title: Mol. Immunol. doi: 10.1016/j.molimm.2021.11.002 – volume: 44 start-page: 838 issue: 6 year: 2022 ident: 13241_CR54 publication-title: Immunopharm Immunot doi: 10.1080/08923973.2022.2086139 – volume: 57 start-page: 242 issue: 4 year: 2018 ident: 13241_CR7 publication-title: Chin. J. Intern. Med. – volume: 13 start-page: 4417 issue: 11 year: 2023 ident: 13241_CR5 publication-title: Acta Pharm. Sin B doi: 10.1016/j.apsb.2023.05.025 – volume: 73 start-page: 336 issue: 4 year: 2007 ident: 13241_CR48 publication-title: Planta Med. doi: 10.1055/s-2007-967136 – volume: 82 start-page: 202 issue: 3 year: 2019 ident: 13241_CR42 publication-title: J. Chin. Med. Assoc. doi: 10.1097/JCMA.0000000000000029 – volume: 72 start-page: 1268 issue: 14 year: 2006 ident: 13241_CR39 publication-title: Planta Med. doi: 10.1055/s-2006-947240 – volume: 14 start-page: 1604 issue: 1 year: 2024 ident: 13241_CR10 publication-title: Sci. REP-UK doi: 10.1038/s41598-023-48248-5 – ident: 13241_CR46 doi: 10.1007/s10753-024-02060-z – volume: 115 start-page: 186 issue: 5 year: 2022 ident: 13241_CR18 publication-title: J. Roy Soc. Med. doi: 10.1177/01410768221093551 – volume: 73 start-page: 136 issue: 1 year: 2007 ident: 13241_CR33 publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2006.08.027 – volume: 166 start-page: 115417 year: 2023 ident: 13241_CR53 publication-title: Biomed. Pharmacother doi: 10.1016/j.biopha.2023.115417 – volume: 14 start-page: 43 year: 2014 ident: 13241_CR23 publication-title: BMC Med. Res. Methodol. doi: 10.1186/1471-2288-14-43 – volume: 171 start-page: 45 year: 2017 ident: 13241_CR16 publication-title: Life Sci. doi: 10.1016/j.lfs.2017.01.004 – volume: 13 start-page: 908227 year: 2022 ident: 13241_CR43 publication-title: Front. Pharmacol. doi: 10.3389/fphar.2022.908227 – volume: 6 start-page: 15 year: 2018 ident: 13241_CR57 publication-title: Bone Res. doi: 10.1038/s41413-018-0016-9 – volume: 19 start-page: 181 issue: 3 year: 2021 ident: 13241_CR55 publication-title: Chin. J. Nat. Med. – volume: 53 start-page: e2249962 issue: 1 year: 2023 ident: 13241_CR21 publication-title: Eur. J. Immunol. doi: 10.1002/eji.202249962 – volume: 14 start-page: 1113810 year: 2023 ident: 13241_CR32 publication-title: Front. Pharmacol. doi: 10.3389/fphar.2023.1113810 – volume: 384 start-page: e70856 year: 2024 ident: 13241_CR1 publication-title: BMJ-BRIT Med. J. – volume: 39 start-page: 191 issue: 2 year: 2019 ident: 13241_CR25 publication-title: J. Tradit Chin. Med. – volume: 133 start-page: 43 issue: 1 year: 2023 ident: 13241_CR30 publication-title: Basic. Clin. Pharmacol. doi: 10.1111/bcpt.13880 – volume: 26 start-page: 197 issue: 1 year: 2021 ident: 13241_CR47 publication-title: Redox Rep. doi: 10.1080/13510002.2021.2004047 |
| SSID | ssj0000529419 |
| Score | 2.4534404 |
| SecondaryResourceType | review_article |
| Snippet | Tripterygium polyglycosides (TG), Triptolide (TP), and Celastrol (CEL), which are extracts from
Tripterygium wilfordii
Hook F (TwHF), are renowned for their... Tripterygium polyglycosides (TG), Triptolide (TP), and Celastrol (CEL), which are extracts from Tripterygium wilfordii Hook F (TwHF), are renowned for their... Abstract Tripterygium polyglycosides (TG), Triptolide (TP), and Celastrol (CEL), which are extracts from Tripterygium wilfordii Hook F (TwHF), are renowned for... |
| SourceID | doaj proquest pubmed crossref springer |
| SourceType | Open Website Aggregation Database Index Database Publisher |
| StartPage | 27960 |
| SubjectTerms | 631/154/436 692/4023/1670/498 Animal model Animal species Animals Anti-Inflammatory Agents - pharmacology Anti-Inflammatory Agents - therapeutic use Arthritis, Experimental - drug therapy Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - pathology Bias Cartilage CD4 antigen Collagen (type II) Disease Models, Animal Diterpenes Dosage Drug dosages Epoxy Compounds Helper cells Humanities and Social Sciences Humans Hyperplasia Immunology Immunomodulation Inflammation Interleukins Joint diseases Lymphocytes T Meta-analysis multidisciplinary Pathogenesis Pentacyclic Triterpenes Phenanthrenes Plant Extracts - chemistry Plant Extracts - pharmacology Plant Extracts - therapeutic use Preclinical studies Rheumatoid arthritis Science Science (multidisciplinary) Software Statistical analysis Systematic review Transforming growth factor-b Tripterygium - chemistry Tripterygium wilfordii Tripterygium wilfordii extracts Triptolide Tumor necrosis factor-TNF Tumor necrosis factor-α γ-Interferon |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuiDcpBRmJG1hN7HFscwNEVSHBaSv1Zjl-0Bw2W212D_0t_FnGcXa3CBAXcnQsx_aMZ76JPZ8JeQPCca2jY633goFpDXNCdQzRrg6u1dy7nOD89Vt7fgFfLuXlrau-8pmwQg9cJu401pELBSnVEcE8eC2Ch2BqUAApdFPggz7vVjBVWL25gcbMWTK10KcjeqqcTcYlwwAMGqZ-8UQTYf-fUOZvO6ST4zl7QO7PiJF-KD19SO7E4RG5W-6QvHlMfiwOGVR0Pp1B3RDoMuak3n5cjnSV6CIbh7i--d5vlxTxcT7T3vcUTXNOkxppP9D1Vdwifl31geK0XE1sR--poweyZ1oSXebmN465mdIkf-EabeecZknHcjrxCbk4-7z4dM7mGxeYF1IoFsAj_EsmGXBdAiWVwXCpk8aB9sLJkFyDCCJhQZCBK4_2smkDhhwiRs2jeEqOhtUQnxOq66gc8CYoRBA8dE7WyUEHySFCEmAq8nY3-_a6EGvYaUNcaFtkZVFWdpKVVRX5mAW0r5lJsacCVBU7q4r9l6pU5GQnXjuv1NEKjhC0EdBCRV7vX-MayxsnboirbakjND6yIs-KWux7ggExZA7Birzb6cmh8b8P6Ph_DOgFucezQk-_mk_I0Wa9jS8RI226V9Ny-AmnuA5F priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkLKs-mLchI3MBqYk9ip5cKEFWFBKettDfL8aPNYZNls3vob-HPdpx4d4V45OhYjuMZj795mpD3IAxXyhtWWSsY1FXNjJANQ7SrnKkUtyYmOH__UV1dw7d5OU8GtyGFVW5l4iioXW-jjfxMcIQKhYAKLpY_Wbw1KnpX0xUaD8mjWLoscrWcy52NJXqxoKhTrkwu1NmA51XMKeMlQzUMCiZ_O4_Gsv1_w5p_-EnH4-fykDxNuJF-mgj9jDzw3XPyeLpJ8u4F-TXb51HRFKNBTefowsfU3nZYDLQPdBZFhF_d3bSbBUWUHCPb25aigI7JUgNtO7q69RtEsX3rKHLV7Vjz6Jwaui_5TKd0lzT82jCTCpvELyxRgqZkSzpMMYovyfXl19mXK5buXWBWlEIyBxZBYKhDDaYJIEtZo9LUlLUBZYUpXTC42nnABlc6Li1KzaJyqHgI7xX34hU56PrOHxGqci8N8MJJxBHcNabMg4EGgkGcJKDOyIft6uvlVF5Dj25xofREK4200iOttMzI50igXc9YGnts6Fc3Ou007XPPhYQQco_aH1glnAVX5yABgmuKjJxuyavTfh30nrsy8m73GndadJ-YzvebqY9Q-JQZeT2xxW4mqBZDrCSYkY9bPtkP_u8fOv7_XE7IEx5ZdTQln5KD9Wrj3yAGWjdvR0a_B9StBZ0 priority: 102 providerName: ProQuest |
| Title | Therapeutic effects and mechanisms of Tripterygium wilfordii extracts in rheumatoid arthritis: a systematic review and meta-analysis of preclinical studies |
| URI | https://link.springer.com/article/10.1038/s41598-025-13241-7 https://www.ncbi.nlm.nih.gov/pubmed/40745443 https://www.proquest.com/docview/3235213464 https://www.proquest.com/docview/3235388885 https://doaj.org/article/e0e2374ff0e1494c83dc4d904744fdb1 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Pa9swFBb9wWCXsd_z2gUNdtvMbOnZkndLQ0sJrIwthdyEbEmtD7FLnBz6t-yf7ZNsJ4x1h-ViUBTH9nt6-p70vs-EfAKumZRWx3lV8RiKvIg1F2WMaFcanUtWaU9w_n6VX17DfJktDwgbuTChaD9IWoYwPVaHfe1wovFkMJbFmD9BGotDcuyl2tG3j6fT-a_5bmXF711BWgwMmYTLR378xywUxPofQ5h_7Y6GSefiOXk2oEU67a_vBTmwzUvypH9_5P0r8nuxZ0_RoTKD6sbQlfWE3rpbdbR1dOEDg13f39TbFUVs7OvZ65piWPYUqY7WDV3f2i1i17Y2FB_GbVA6-kY13Qs9057kMpx-o2M9yJn4f7jDuDlQLGnXVya-JtcX54vZZTy8bSGueMZFbKBC6OcKV4AuHYhMFJgqlVmhQVZcZ8bpFNGDwwaTGSYqjJVpbjDd4NZKZvkbctS0jX1HqEys0MBSIxA9MFPqLHEaSnAa0RGHIiKfx6ev7npRDRU2w7lUva0U2koFWykRkTNvoF1PL4gdGtr1jRocRNnEMi7AucRizgeV5KYCUyQgAJwp04icjuZVwyjtFGcIP1MOOUTk4-5rHF9-00Q3tt32fbjETxaRt71b7K4Ek2Hw-oER-TL6yf7k_76h9__X_YQ8Zd51w4LyKTnarLf2AyKhTTkhh2IpJsMAwOPZ-dWPn9g6y2eTsLrwAJG-CSU |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELaWRQguiDeBBYwEJ7A2sSexg4QQr1WXfZy6Um_Gie3dHJqUphXqb-E_8BsZJ2krxOO2OSaR85jxzDcefzOEvABhuFLOsKwsBYM8y5kRsmCIdpU1meKlCQTnk9NsdAZfJulkh_xcc2HCtsq1TewMtW3KsEa-LzhChURABu9m31joGhWyq-sWGr1aHLnVdwzZ2reHn1C-Lzk_-Dz-OGJDVwFWilRIZqFEiONzn4MpPMhU5hgSFGluQJXCpNabBL2kxxM2tVyWaBOSzCKsFs4p7gSOe4VcRccbh2BPTuRmTSdkzSDJB25OLNR-i_4xcNh4yjDsg4TJ3_xf1ybgb9j2j7xs5-4ObpGbA06l73vFuk12XH2HXOs7V67ukh_jLW-LDntCqKktnbpAJa7aaUsbT8fBJLn56rxaTimi8rCTvqooOoRAzmppVdP5hVsiam4qS1GLL7oaS2-oodsS07Sn1wzDLwwzQyGV8IQZWuyB3Enbfk_kPXJ2KRK5T3brpnYPCVWxkwZ4YiXiFm4Lk8beQAHeIC4TkEfk1frv61lfzkN3aXihdC8rjbLSnay0jMiHIKDNnaEUd3eimZ_rYWZrFzsuJHgfO4w2oVTClmDzGCSAt0USkb21ePVgH1q91eaIPN9cxpkd0jWmds2yv0coPNKIPOjVYvMmGIZDqFwYkddrPdkO_u8PevT_d3lGro_GJ8f6-PD06DG5wYPadsvYe2R3MV-6J4i_FsXTTukp-XrZs-wXf3VBkA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKViAuFW9SChgJThBtYjuxg4QQpV21FFYV2kq9uU5stzlssmx2hfa38E_4dYwTZ1eIx605JpHzmPH4G898Mwi9ZFQRIYwK06KgIcvSLFSU5yGgXaFVKkihHMH5yzg9OmOfzpPzLfSz58K4tMreJraGWteF2yMfUgJQIaYsZUPr0yJOD0bvZ99C10HKRVr7dhqdipyY1Xdw35p3xwcg61eEjA4nH49C32EgLGhCeahZAXDHZjZjKreMJzwD9yBPMsVEQVWirYphxbRwQiea8ALsQ5xqgNjUGEEMhXFvoG3uvKIB2t4_HJ9-Xe_wuBgaizPP1ImoGDawWjpGG0lCcAJZHPLfVsO2acDfkO4fUdp28RvdQTseteIPnZrdRVumuodudn0sV_fRj8mGxYV9hghWlcZT44jFZTNtcG3xxBkoM19dlsspBozu8urLEsM_dlStBpcVnl-ZJWDoutQYdPqqrbj0Fiu8KTiNO7KNH36hQuXLqrgnzMB-e6onbroMyQfo7Fpk8hANqroyjxEWkeGKkVhzQDFE5yqJrGI5swpQGmVZgF73f1_OuuIesg3KUyE7WUmQlWxlJXmA9p2A1ne6wtztiXp-Kf08lyYyhHJmbWTA92SFoLpgOosYZ8zqPA7QXi9e6a1FIze6HaAX68swz13wRlWmXnb3UAFHEqBHnVqs3wTUj7k6hgF60-vJZvB_f9Du_9_lOboFM0x-Ph6fPEG3idPadk97Dw0W86V5CmBskT_zWo_RxXVPtF_6xUcr |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+effects+and+mechanisms+of+Tripterygium+wilfordii+extracts+in+rheumatoid+arthritis%3A+a+systematic+review+and+meta-analysis+of+preclinical+studies&rft.jtitle=Scientific+reports&rft.au=Chen%2C+Kai&rft.au=Chen%2C+Xiaoying&rft.au=Huang%2C+Shuai&rft.au=Zhou%2C+Lingling&rft.date=2025-07-31&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=15&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-025-13241-7&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41598_025_13241_7 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |